MEK and MAF in myeloma therapy
| العنوان: | MEK and MAF in myeloma therapy |
|---|---|
| المؤلفون: | Relja Popovic, Jonathan D. Licht |
| المصدر: | Blood. 117:2300-2302 |
| بيانات النشر: | American Society of Hematology, 2011. |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Oncogene, Bortezomib, Molecular pathology, business.industry, Immunology, Cell Biology, Hematology, Disease, medicine.disease, Biochemistry, Thalidomide, immune system diseases, hemic and lymphatic diseases, medicine, Extracellular, Cancer research, business, Protein kinase A, Multiple myeloma, medicine.drug |
| الوصف: | Despite increased understanding of molecular pathogenesis of multiple myeloma and implementation of therapies such as bortezomib and thalidomide, only 10% of patients survive more than 10 years after diagnosis. Until recently, new therapies for myeloma have not been developed based on a detailed understanding of the molecular pathology of the disease. In this issue of Blood, Annunziata et al report a rationale for the use of mitogen-activated or extracellular signal-regulated protein kinase (MEK) inhibitors in the subset of myeloma patients expressing high levels of the MAF oncogene. |
| تدمد: | 1528-0020 0006-4971 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::f1b1a8d257ec1f39dc2cf338177c06cbTest https://doi.org/10.1182/blood-2011-01-327262Test |
| رقم الانضمام: | edsair.doi...........f1b1a8d257ec1f39dc2cf338177c06cb |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15280020 00064971 |
|---|